Featured stories

• 15/05/25 LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%
• 13/05/25 To sharpen focus on the global commercialization of strategic products and the external partnership model, LEO Pharma makes changes to leadership
• 09/05/25 LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis
• 14/04/25 LEO Pharma and the Parker Institute Partner to Advance Skin Disease Research
• 05/03/25 Liisa Hurme and Mark Levick elected to LEO Pharma’s Board of Directors
• 26/02/25 LEO Pharma delivers double-digit revenue growth and strong progress for strategic transformation
• 05/02/25 DEBRA Research and LEO Pharma Announce Strategic Partnership to Advance Treatments for Rare Skin Diseases
• 29/01/25 LEO Pharma Announces Changes to Executive Leadership
• 11/01/25 Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
• 07/11/24 LEO Pharma gears for growth with senior leadership changes
• 31/10/24 LEO Pharma continues to deliver double-digit revenue growth backed by strong dermatology sales
• 11/10/24 LEO Pharma commits to net-zero greenhouse gas emissions by 2050
• 26/08/24 LEO Pharma delivers 11% revenue growth (CER) in H1 and upgrades financial outlook for the year
• 21/08/24 Timber Pharmaceuticals, Inc., a LEO Pharma Company, provides an update on the development program for TMB-001 in congenital ichthyosis
• 31/07/24 Change in the Board of Directors of LEO Pharma
• 04/07/24 LEO Pharma announces changes to its Global Leadership Team
• 01/06/24 Recognized professor joins LEO Pharma to accelerate external innovation
• 03/05/24 Solid start to the year: 13% revenue growth driven by strong performance in dermatology
• 29/02/24 LEO Pharma announces annual results 2023
• 23/01/24 LEO Pharma finalizes acquisition of key assets from Timber Pharmaceuticals.
• 09/10/23 Globally known professor and dermatologist joins LEO Pharma
• 12/09/23 LEO Pharma delivers solid first half-year results and strengthens its capital structure
• 28/08/23 LEO Pharma announces changes to its Global Leadership Team
• 21/08/23 LEO Pharma Signs Agreement to Acquire Timber Pharmaceutical
• 20/06/23 LEO Pharma announces changes to its Global Leadership Team
• 14/03/23 LEO Pharma adds internationally recognized dermatologist to Global Leadership Team
• 10/03/23 LEO Pharma and ICON enter a Strategic Partnership to propel clinical trial execution within medical dermatology
• 09/03/23 LEO Pharma announces annual results 2022
• 12/01/23 Delivering a financial turnaround of LEO Pharma
• 31/08/22 LEO Pharma appoints Paul Navarre new member of its Board of Directors
• 18/08/22 LEO Pharma appoints new Chief Financial Officer and Executive Vice President
• 03/08/22 LEO Pharma appoints new Executive Vice President of Global Product Supply
• 28/06/22 LEO Pharma appoints Elisabeth Svanberg new member of its Board of Directors
• 02/06/22 LEO Pharma strengthens its commercial organization
• 21/04/22 LEO Pharma’s emission reduction targets validated by the Science Based Targets initiative
• 17/03/22 LEO Pharma announces annual results 2021
• 17/02/22 LEO Pharma A/S appoints Brian Hilberdink new President of LEO Pharma Inc. United States
• 31/01/22 LEO Pharma appoints Christophe Bourdon as new CEO
• 19/01/22 LEO Pharma introduces new operating model to increase competitiveness and support future growth
• 05/01/22 LEO Pharma convene dermatology experts in global initiative on skin health
• 30/11/21 Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma
• 15/11/21 LEO Pharma successfully refinances loan facility
• 29/09/21 LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials
• 06/07/21 LEO Pharma and X-Chem Enter Into Discovery Research Agreement
• 22/03/21 LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 2020
• 15/12/20 LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development
• 27/10/20 LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day
• 22/09/20 LEO Pharma strengthens global leadership team with appointment of new Executive Vice President, Global Therapeutic & Value Strategy
• 30/08/20 LEO Pharma sells portfolio of four products to Cheplapharm
• 19/08/20 LEO Pharma unveils ambitious 2030 strategy positioning itself for long-term growth driven by innovation
• 18/08/20 LEO Pharma strengthens global leadership team with appointment of new EVP People & Communications
• 29/06/20 LEO Pharma strengthens global leadership team
• 12/03/20 Updates regarding COVID-19
• 20/11/19 LEO Pharma launches Open Innovation in Ontario to support the innovation ecosystem in the province
• 18/11/19 LEO Pharma launches Open Innovation program and partnership with the University of Victoria in Canada
• 13/11/19 Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors
• 06/11/19 LEO Science & Tech Hub and Epicore Biosystems Announce Second Phase of Partnership
• 29/10/19 LEO Pharma enters into option agreement with Ubiquigent for access to novel compounds
• 23/10/19 World Psoriasis Day 2019: LEO Pharma launches new campaign to reduce the stigma surrounding psoriasis
• 30/06/19 LEO Pharma completes the acquisition of Bayer’s prescription dermatology business
• 02/06/19 LEO Pharma appoints Catherine Mazzacco as new CEO
• 09/05/19 LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
• 10/04/19 LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
• 08/04/19 LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
• 18/03/19 LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment